Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 19.

Cozzi-Lepri, A; Zangerle, R; Machala, L; Zilmer, K; Ristola, M; Pradier, C; Kirk, O; Sambatakou, H; Fätkenheuer, G; Yust, I; Schmid, P; Gottfredsson, M; Khromova, I; Jilich, D; Flisiak, R; Smidt, J; Rozentale, B; Radoi, R; Losso, M H; Lundgren, J D; Mocroft, A; EuroSIDA Study Group (2017). Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. HIV Medicine:Epub ahead of print.

Shepherd, L; Borges, Áh; Ledergerber, B; Domingo, P; Castagna, A; Rockstroh, J; Knysz, B; Tomazic, J; Karpov, I; Kirk, O; Lundgren, J; Mocroft, A (2016). Infection-related and -unrelated malignancies, HIV and the aging population. HIV Medicine, 17(8):590-600.

Achhra, A C; Mocroft, A; Reiss, P; Sabin, C; Ryom, L; de Wit, S; Smith, C J; d'Arminio Monforte, A; Phillips, A; Weber, R; Lundgren, J; Law, M G (2016). Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Medicine, 17(4):255-268.

Ledergerber, B; Costagliola, D; Lodwick, R; Torti, C; van Sighem, A; Podzamczer, D; Mocroft, A; Dorrucci, M; Masquelier, B; Günthard, H F; de Luca, A; Michalik, C (2013). Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Journal of Infectious Diseases, 207(5):759-767.

Grint, D; Peters, L; Reekie, J; Soriano, V; Kirk, O; Knysz, B; Suetnov, O; Lazzarin, A; Ledergerber, B; Rockstroh, J K; Mocroft, A (2013). Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. HIV Medicine, 14(6):370-378.

Mocroft, A; Furrer, H J; Miro, J M; Reiss, P; Mussini, C; Kirk, O; Abgrall, S; Ayayi, S; Bartmeyer, B; Braun, D; Castagna, A; d'Arminio Monforte, A; Gazzard, B; Gutierrez, F; Hurtado, I; Jansen, K; Meyer, L; Muñoz, P; Obel, N; Soler-Palacin, P; Papadopoulos, A; Raffi, F; Ramos, J T; Rockstroh, J K; Salmon, D; Torti, C; Warszawski, J; de Wit, S; Zangerle, R; Fabre-Colin, C; Kjaer, J; Chene, G; Grarup, J; Lundgren, J D (2013). The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Clinical Infectious Diseases, 57(7):1038-1047.

Mocroft, A; Phillips, A; Gatell, J; Horban, A; Ledergerber, B; Zilmer, K; Jevtovic, D; Maltez, F; Kirk, O; Lundgren, J (2012). CD4 count and viral load specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. Journal of the International Aids Society, 15(6):18191.

Kowalska, J D; Reekie, J; Mocroft, A; Reiss, P; Ledergerber, B; Gatell, J; D'Arminio Monforte, A; Phillips, A; Lundgren, J D; Kirk, O (2012). Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. AIDS, 26(3):315-323.

Reekie, J; Reiss, P; Ledergerber, B; Sedlacek, D; Parczewski, M; Gatell, J; Katlama, C; Fätkenheuer, G; Lundgren, J D; Mocroft, A (2011). A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. HIV Medicine, 12(5):259-268.

Kowalska, J D; Mocroft, A; Ledergerber, B; Florence, E; Ristola, M; Begovac, J; Sambatakou, H; Pedersen, C; Lundgren, J D; Kirk, O (2011). A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study. HIV Clinical Trials, 12(2):109-117.

Lodwick, R K; Sabin, C A; Porter, K; Ledergerber, B; van Sighem, A; Cozzi-Lepri, A; Khaykin, P; Mocroft, A; Jacobson, L; De Wit, S; Obel, N; Castagna, A; Wasmuth, J C; Gill, J; Klein, M B; Gange, S; Riera, M; Mussini, C; Gutiérrez, F; Touloumi, G; Carrieri, P; Guest, J L; Brockmeyer, N H; Phillips, A N (2010). Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet, 376(9738):340-345.

Mocroft, A; Phillips, A N; Ledergerber, B; Smith, C; Bogner, J R; Lacombe, K; Wiercinska-Drapalo, A; Reiss, P; Kirk, O; Lundgren, J D (2010). Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. Antiviral Therapy, 15(4):563-570.

Mocroft, A; Kirk, O; Reiss, P; De Wit, S; Sedlacek, D; Beniowski, M; Gatell, J; Phillips, A N; Ledergerber, B; Lundgren, J D (2010). Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS, 24(11):1667-1678.

Reekie, J; Mocroft, A; Ledergerber, B; Beniowski, M; Clotet, B; van Lunzen, J; Chiesi, A; Pradier, C; Machala, L; Lundgren, J D (2010). History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change. HIV Medicine, 11(7):469-478.

Mocroft, A; Reiss, P; Gasiorowski, J; Ledergerber, B; Kowalska, J; Chiesi, A; Gatell, J; Rakhmanova, A; Johnson, M; Kirk, O; Lundgren, J (2010). Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. Journal of Acquired Immune Deficiency Syndrome, 55(2):262-270.

Lodwick, R; Costagliola, D; Reiss, P; Torti, C; Teira, R; Dorrucci, M; Ledergerber, B; Mocroft, A; Podzamczer, D; Cozzi-Lepri, A; Obel, N; Masquelier, B; Staszewski, S; García, F; De Wit, S; Castagna, A; Antinori, A; Judd, A; Ghosn, J; Touloumi, G; Mussini, C; Duval, X; Ramos, J; Meyer, L; Warsawski, J; Thorne, C; Masip, J; Pérez-Hoyos, S; Pillay, D; van Sighem, A; Lo Caputo, S; Günthard, H; Paredes, R; De Luca, A; Paraskevis, D; Fabre-Colin, C; Kjaer, J; Chêne, G; Lundgren, J D; Phillips, A N (2010). Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Archives of Internal Medicine, 170(5):410-419.

Peters, L; Mocroft, A; Soriano, V; Rockstroh, J K; Losso, M; Valerio, L; Aldins, P; Reiss, P; Ledergerber, B; Lundgren, J D (2009). Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. JAIDS Journal of Acquired Immune Deficiency Syndromes, 50(5):457-463.

Podlekareva, D; Mocroft, A; Kirk, O; Reiss, P; Aldins, P; Katlama, C; Kovari, H; Stellbrink, H J; D'Arminio Monforte, A; Lundgren, J D (2008). Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART. Scandinavian Journal of Infectious Diseases, 40(11):908-913.

Soriano, V; Mocroft, A; Rockstroh, J; Ledergerber, B; Knysz, B; Chaplinskas, S; Peters, L; Karlsson, A; Katlama, C; Toro, C; Kupfer, B; Vogel, M; Lundgren, J; EuroSIDA Study, Group (2008). Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. Journal of Infectious Diseases, 198(9):1337-1344.

This list was generated on Fri Nov 17 23:24:33 2017 CET.